Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Açın
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0,21%
1.091,51
-2,30
-0,21%
—1.093,811.096,521.100,221.091,51——
SIXC
Communications
SIXC
Communications
SIXC
+0,22%
610,11
+1,34
+0,22%
—608,77608,77612,97608,77——
SIXE
Energy
SIXE
Energy
SIXE
-1,34%
1.237,98
-16,83
-1,34%
—1.254,811.253,011.253,871.226,33——
SIXI
Industrials
SIXI
Industrials
SIXI
-0,93%
1.744,71
-16,40
-0,93%
—1.761,111.764,271.766,881.744,71——
SIXM
Financials
SIXM
Financials
SIXM
-0,37%
640,18
-2,40
-0,37%
—642,58644,87648,48640,18——
SIXR
Staples
SIXR
Staples
SIXR
-0,18%
849,58
-1,55
-0,18%
—851,13855,66858,75845,56——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0,23%
217,48
-0,50
-0,23%
—217,98217,98218,65216,88——
SIXT
Technology
SIXT
Technology
SIXT
+1,52%
3.260,69
+48,86
+1,52%
—3.211,833.227,213.268,383.226,55——
SIXU
Utilities
SIXU
Utilities
SIXU
-0,69%
942,45
-6,53
-0,69%
—948,98948,58957,83941,97——
SIXV
Health care
SIXV
Health care
SIXV
-0,52%
1.466,80
-7,72
-0,52%
—1.474,521.479,031.481,041.466,80——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0,22%
2.397,50
+5,38
+0,22%
—2.392,122.396,952.421,222.382,32——
CVG:FRA
CSPC Pharmaceutical Group Ltd
0,89 €
-0,22%
(-0,0020) 1D
30 apr, 22:00:00 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for CVG...
Açın
0,89 €
High
0,89 €
Low
0,89 €
Mkt. cap
96,90 mlrd
Avg. vol.
101,00
Volume
0,00
52-wk high
1,25 €
52-wk low
0,63 €
No. of employees
20K
News stories
From sources across the web
Profile
CSPC Pharmaceutical Group researches, develops, manufactures and sells pharmaceutical products. Its headquarters is in China's Hebei Province. CSPC produces both active pharmaceutical ingredient and formulations. API products include penicillin, cefalosporins, synthetic vitamins, caffeine and ranitidine. Formulations include antibiotics, butylphthalide and analgesics, in addition to nearly 1,000 other products. CSPC's 15,000 employees are divided among more than ten subsidiaries, including CSPC Zhongrun, Weisheng, Zhongnuo and NBP. CSPC Pharma's total assets are valued above RMB 8 billion. In 2007, CSPC Pharma achieved sales of RMB 8 billion and net income of RMB 485 million. Direct exports of US$300 million ranked CSPC first among China's pharmaceutical enterprises. One subsidiary, China Pharmaceutical Group Co., Ltd is based in Hong Kong. It is listed on the Hang Seng China-Affiliated Corporations Index. In 2003 and 2004, China Pharma was listed as one of 100 excellent listed companies with turnover less than $1 billion. CSPC Pharma is recognized as one of China's “500 Most Valuable Chinese Brands” and “Top 500 Chinese Enterprises.” Wikipedia
About CSPC Pharmaceutical Group Ltd
CEOZhang Cuilong
Employees19,7K
Founded1992
Headquarters-
SectorPharmaceutical industry
Websitecspc.com.hk
Previous reportsAll values in HKD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
mar 2025
iyn 2025
sen 2025
dek 2025
Revenue
7,01 mlrd
6,26 mlrd
6,62 mlrd
6,11 mlrd
Cost of goods sold
2,31 mlrd
2,25 mlrd
2,28 mlrd
2,11 mlrd
Cost of revenue
2,31 mlrd
2,25 mlrd
2,28 mlrd
2,11 mlrd
Research and development expenses
1,30 mlrd
1,38 mlrd
1,50 mlrd
1,62 mlrd
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,89 mlrd
1,56 mlrd
1,97 mlrd
1,87 mlrd
Operating expense
3,19 mlrd
2,94 mlrd
3,47 mlrd
3,49 mlrd
Total operating expenses
5,50 mlrd
5,20 mlrd
5,75 mlrd
5,60 mlrd
Operating income
1,51 mlrd
1,06 mlrd
869,63 mln
514,71 mln
Other non operating income
278,47 mln
3,60 mln
645,49 mln
-470,42 mln
EBT including unusual items
1,80 mlrd
1,32 mlrd
1,18 mlrd
505,59 mln
EBT excluding unusual items
1,80 mlrd
1,14 mlrd
1,37 mlrd
186,56 mln
Income tax expense
301,26 mln
242,36 mln
222,47 mln
165,64 mln
Effective tax rate
16,77%
18,34%
18,78%
32,76%
Other operating expenses
-
-
-
-
Net income
1,48 mlrd
1,07 mlrd
963,54 mln
370,72 mln
Net profit margin
21,07%
17,09%
14,56%
6,06%
Earnings per share
-
-
-
-
Interest and investment income
-
95,00 mln
-
195,87 mln
Interest expense
-6,74 mln
-14,91 mln
-105,19 mln
-6,76 mln
Net interest expenses
-6,74 mln
80,09 mln
-105,19 mln
189,12 mln
Depreciation and amortization charges
-
-
-
-
EBITDA
1,79 mlrd
1,36 mlrd
1,14 mlrd
802,06 mln
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer